| Value | ₹100.0 Cr |
|---|
NSE filing, NSE: MEESHO. Summary written from the filing by ALFA Finder's alert engine.
Meesho Ltd: key numbers
- Share price
- ₹223.01
- Market cap
- ₹1,03,228 Cr
- Revenue (annual)
- ₹12,626 Cr
- Net profit (annual)
- ₹-1,358 Cr
- P/E (TTM)
- -111.9×Sector 61.8×
- Promoter holding
- 16.34%-0.07% QoQ
- FII holding
- 9.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Meesho Ltd
All →Meesho Merger & Restructuring Worth ₹15 Cr
Meesho will incorporate a wholly owned financial services subsidiary with an initial investment of up to Rs.15 Crore. The subsidiary has not yet commenced business.
- Value
- ₹15.00 Cr
Meesho Acquisition Worth ₹50 Cr
Meesho approved up to Rs.50 Crore further investment in Retail Pulse Labs, payable in tranches. It follows the Kirana Club acquisition, making RPLPL a step-down subsidiary.
- Value
- ₹50.00 Cr
- Execution
- Within 1 year from the closing of the first tranche of the original acquisition
Meesho Acquisition Worth ₹18.74 Cr
Meesho will acquire a further stake in Retail Pulse Labs for ₹18.74 Crore cash. The step-down deal depends on completing the first Kirana Club tranche.
- Value
- ₹18.74 Cr
Meesho Acquisition Worth ₹6.17 Cr
Meesho will acquire 100% of Singapore-based Kirana Club in cash, up to USD 6.5 lakh in tranches. The target runs a digital platform for grocery retailers.
- Value
- ₹6.17 Cr
Meesho Capital Structure Change
Meesho will invest up to USD 1 lakh in cash, in tranches, in its wholly owned US subsidiary. Its 100% holding stays unchanged, worth about ₹0.01 Crore.
- Value
- ₹0.01 Cr
Meesho Management Change
Meesho appointed Sudhir Ganesh Sitapati as Additional Non-Executive Independent Director for 60 months, effective 28 October 2026. He is a former Godrej Consumer Products MD and CEO.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr